Navigation Links
Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
Date:9/13/2007

SAN DIEGO, Sept. 13 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to provide a corporate overview of its clinical development and discovery programs at four upcoming investor conferences:

-- ThinkEquity Partners' 5th Annual Growth Conference

Presentation: Monday, September 17, 2007 at 10:00 a.m. Pacific Time

(1:00 p.m. Eastern Time) at the St. Regis Hotel in San Francisco

Presenting: Jack Lief, Arena's President and Chief Executive Officer

-- Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference 2007

Presentation: Wednesday, September 19, 2007 at 11:20 a.m. British

Summer Time (6:20 a.m. Eastern Time, 3:20 a.m. Pacific Time) at the

Merrill Lynch Financial Centre in London

Presenting: Jack Lief, Arena's President and Chief Executive Officer

-- A.G. Edwards' Emerging Growth Conference 2007

Presentation: Wednesday, September 19, 2007 at 12:30 p.m. Eastern Time

(9:30 a.m. Pacific Time) at the New York Palace Hotel in New York City

Presenting: Robert E. Hoffman, Arena's Vice President, Finance and

Chief Financial Officer

-- Maxim Group Growth Conference

Presentation: Thursday, September 20, 2007 at 10:30 a.m. Eastern Time

(7:30 a.m. Pacific Time) at the Grand Hyatt Hotel in New York City

Presenting: Robert E. Hoffman, Arena's Vice President, Finance and

Chief Financial Officer

A live audio webcast of each presentation will be available under the investor relations section of Arena's website at http://www.arenapharm.com. Please connect to Arena's website several minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory, and metabolic diseases. Arena's most advanced product candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated independently and with its partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, preclinical and internal and partnered clinical programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, Arena's planned clinical trials may not proceed at the time Arena expects or at all, the results of preclinical studies or clinical trials may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contacts: Jack Lief Mary Claire Duch

President and CEO WeissComm Partners

Media Relations

David Walsey 212.301.7228

Director, Corporate Communications

Arena Pharmaceuticals, Inc.

858.453.7200, ext. 1682


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2020)... ... June 23, 2020 , ... Construction at the ... now features a greatly enlarged and enhanced medical facility. Penetron crystalline technology ... tanks, and rooftop garden. , Part of the Bangkok Chain Hospital (BCH) network ...
(Date:6/19/2020)... ... June 19, 2020 , ... The Covid-19 pandemic has had ... Establishing a safe environment and compliant workforce is critical in the post-Covid world. , ... its popular SupplyBay vending machine below cost for a limited time only. , ...
(Date:6/19/2020)... NEW YORK (PRWEB) , ... ... ... announces the launch of its cross-platform campaign 'Clinical Trials.' This campaign showcases ... who participate in these studies, thereby advancing knowledge and disease treatment. This ...
Breaking Medicine Technology:
(Date:7/1/2020)... Texas (PRWEB) , ... July 01, 2020 , ... ... announced today that it has been selected by Codiak BioSciences to support its ... PODs will provide the cleanroom infrastructure for the drug substance and product manufacturing ...
(Date:6/28/2020)... ... June 26, 2020 , ... ... and the general public. As a supplier of top-quality masks, sanitizers and thermometers, ... for PPE equipment. President Priya Agarwal observed, “All of our masks are manufactured ...
(Date:6/25/2020)... ... June 25, 2020 , ... Denials Management, Inc. has ... the key steps when filing appeals for denials of mental health and substance use ... educate individuals about their appeal rights and explain the steps in the appeals process. ...
(Date:6/24/2020)... ... June 24, 2020 , ... The world’s largest cell phone trade-in price comparison ... cell phones will be worth the most two years after purchase. , The ... Samsung, Google, Sony and LG - and compared their 2018 MSRP with their trade ...
(Date:6/23/2020)... Columbia (PRWEB) , ... June 23, 2020 , ... ... Dr. Mike Hart has been named as the President of North America’s ... experience in plant based therapy, including owning and operating his own family medicine clinic ...
Breaking Medicine News(10 mins):